SCHEMBL10244787

SCHEMBL10244787

CCCCNC(=O)c1c[nH]c2ccccc12

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 3/20 0.67
HDAC2 Q92769 2/20 0.67
HDAC3 O15379 2/20 0.67
HDAC4 P56524 1/20 0.67
HDAC7 Q8WUI4 1/20 0.67
HDAC10 Q969S8 1/20 0.67
HDAC11 Q96DB2 1/20 0.67
HDAC8 Q9BY41 1/20 0.67
HDAC6 Q9UBN7 1/20 0.67
HDAC9 Q9UKV0 1/20 0.67
HDAC5 Q9UQL6 1/20 0.67
TSHR P16473 1/20 0.62
HTT P42858 1/20 0.62
GABRA1 P14867 1/20 0.56
GABRB2 P47870 1/20 0.56
HPGD P15428 1/20 0.55
MTNR1A P48039 1/20 0.54
POLB P06746 1/20 0.54
PBRM1 Q86U86 1/20 0.54
NR4A2 P43354 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16596188 0.94 HDAC1 (0.71) HDAC1HDAC2HDAC3HDAC4HDAC7
SCHEMBL10288963 0.91 HDAC1 (0.62) HDAC1HDAC2HDAC3HDAC4HDAC7
SCHEMBL7135416 0.87 GABRA1 (0.64) HDAC1HDAC2HDAC3HDAC4HDAC7
SCHEMBL31060147 0.86 POLB (0.73) GABRA1GABRB2POLBMEN1KMT2A
SCHEMBL18229443 0.85 GABRA1 (0.63) HDAC1HDAC2HDAC3HDAC4HDAC7
SCHEMBL12903051 0.85 PBRM1 (0.60) HDAC1HDAC2HDAC3HDAC4HDAC7
SCHEMBL17117417 0.83 POLB (0.77) HDAC1HDAC2HDAC3HDAC4HDAC7
SCHEMBL20182233 0.83 PYGL (0.68) HDAC1HDAC2HDAC3HDAC4HDAC7
SCHEMBL20267057 0.82 HDAC1 (0.62) HDAC1HDAC2HDAC3HDAC4HDAC7
SCHEMBL9165425 0.82 EGFR (0.59) HDAC1HDAC2HDAC3HDAC4HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 HDAC1 34/4885HDAC2 197/4885HDAC3 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.